title: Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature.
abstract: Phosphodiesterase type 5 (PDE5) inhibitors are the most commonly used treatment for erectile dysfunction (ED). Since the launch of sildenafil, several drugs-including mirodenafil, sildenafil citrate (sildenafil), tadalafil, vardenafil HCL (vardenafil), udenafil, and avanafil-have become available. Mirodenafil is a newly developed pyrrolopyrimidinone compound, which is a potent, reversible, and selective oral PDE5 inhibitor. Mirodenafil was launched in Korea in 2007, and an orally disintegrating film of mirodenafil was developed in 2011 for benefitting patients having difficulty in swallowing tablets. This study aimed to review the pharmacokinetic characteristic profile of mirodenafil and report evidence on its efficacy in the case of ED. In addition, we reviewed randomized controlled studies of mirodenafil's daily administration and efficacy for lower urinary tract symptoms.
authors.affiliation: Department of Urology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
authors.forename: Hyun Jun
authors.initials: HJ
authors.lastname: Park
authors.affiliation: Department of Urology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
authors.forename: Kyung Hyun
authors.initials: KH
authors.lastname: Moon
authors.affiliation: Department of Urology, Hanyang University Guri Hospital, Guri, Korea.
authors.forename: Seung Wook
authors.initials: SW
authors.lastname: Lee
authors.affiliation: Department of Urology, Chuncheon Sacred Heart Hospital, Hallym Unversity College of Medicine, Chuncheon, Korea.
authors.forename: Won Ki
authors.initials: WK
authors.lastname: Lee
authors.affiliation: Department of Urology, Gyeongsang National University School of Medicine, Jinju, Korea.
authors.forename: Sung Chul
authors.initials: SC
authors.lastname: Kam
authors.affiliation: Department of Urology, National Police Hospital, Seoul, Korea.
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Lee
authors.affiliation: Department of Urology, Medical Research Institute, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Korea.
authors.forename: Nam Cheol
authors.initials: NC
authors.lastname: Park
keywords: Erectile dysfunction; Phosphodiesterase 5 inhibitors; Review; Treatment efficacy